InvestorsHub Logo
Followers 971
Posts 383013
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Tuesday, 07/11/2023 4:07:19 PM

Tuesday, July 11, 2023 4:07:19 PM

Post# of 2791
Nascent Biotech Inc. NBIO is an emerging player in the $4 billion oncology drug development space with a legitimate IP asset possibly heading into Phase 2 clinical research for its first flagship pipeline asset. Besides the good news that it appears to have successfully navigated Phase 1 research, this stage of development is of particular interest to institutional money managers involved in the biotech space.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News